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Objectives This study sought to compare late safety and efﬁcacy outcomes following percutaneous
coronary revascularization with zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES).
Background Despite higher late lumen loss and binary restenosis with ZES compared with SES, it is uncer-
ain whether differences in early angiographic measures translate into more disparate late clinical events.
ethods Clinical outcomes were prospectively evaluated through 5 years in the ENDEAVOR III (A
andomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent Sys-
em Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery
esions) that randomized 436 patients of relatively low anatomic and clinical risk to treatment with
ES (n  323) or SES (n  113) and evaluated a primary endpoint of 8-month angiographic late
lumen loss.
Results At 5 years (completeness of follow-up: 95.2%), pre-speciﬁed endpoints of all-cause mortality
(5.2% vs. 13.0%, p  0.02), myocardial infarction (1.0% vs. 4.6%, p  0.03), and the composite event
rates of cardiac death/myocardial infarction (1.3% vs. 6.5%, p  0.009) and major adverse car-
diac events (14.0% vs. 22.2%, p  0.05) were signiﬁcantly lower among patients treated with
ZES. Rates of target lesion (8.1% ZES vs. 6.5% SES, p  0.68) and target vessel revascularization
were similar between treatment groups. Stent thrombosis was infrequent and similar in both groups
(0.7% ZES vs. 0.9% SES, p  1.0). Between 9 months and 5 years, progression of major adverse cardiac
events was signiﬁcantly more common with SES than with ZES (16.7% vs. 7.8%, p  0.015).
Conclusions Despite initially higher angiographic late lumen loss, rates of clinical restenosis be-
yond the protocol-speciﬁed angiographic follow-up period remain stable with ZES compared
with the rates for SES, resulting in similar late-term efﬁcacy. Over 5 years, signiﬁcant differences
in death, myocardial infarction, and composite endpoints favored treatment with ZES. (The
Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial [ENDEAVOR III];
NCT00217256) (J Am Coll Cardiol Intv 2011;4:543–50) © 2011 by the American College of
Cardiology Foundation
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544A common theme of early drug-eluting stent (DES) trials
involved the comparison of angiographic surrogate indexes
related to the antiproliferative effect of DES and reduction in
neointimal hyperplasia (1–3). Correlating angiographic results
ith intermediate-term (e.g., 9- to 12-month) revasculariza-
ion rates, predictive models were designed to estimate the
ikelihood of revascularization, extrapolating the relationship
etween biological and clinical efficacy for any particular DES
4–6). In comparison with late lumen loss or angiographic
estenosis as endpoints, more contemporary trials directed
oward patient-oriented clinical outcomes have identified
merging differences in late efficacy and safety events between
ES that are less closely linked to early measures (7–10).
See page 551
The ENDEAVOR III (A Randomized Controlled Trial
of the Medtronic Endeavor Drug [ABT-578] Eluting
Coronary Stent System Versus
the Cypher Sirolimus-Eluting
Coronary Stent System in De
Novo Native Coronary Artery
Lesions) was a randomized eval-
uation of angiographic late lu-
men loss as a primary endpoint
among patients undergoing per-
cutaneous coronary revascular-
ization with zotarolimus-eluting
stents (ZES) (Endeavor, Medtronic
Cardiovascular, Santa Rosa, Cali-
fornia) and sirolimus-eluting stents
(SES) (Cypher, Cordis Corpora-
tion, Bridgewater, New Jersey) (3).
In this study, angiographic mea-
sures of late lumen loss and reste-
osis were significantly higher with ZES and were also
ssociated a small relative difference in target lesion revascular-
zation (TLR) that was not statistically significant, with no
ifference in death or myocardial infarction (MI) at 9 months.
s part of the planned 5-year follow-up, an important focus of
he investigation is not only to compare events relative to
ES assignment, but also to try to determine whether
he early observation of greater neointimal hyperplasia
ith ZES is associated with progression of adverse events
eyond the initial study report. Therefore, we evaluated
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served as a consultant for Abbott Vascular, Boston Scientific, Cordis Corporation,
Lilly, and Medtronic, and as a speaker for Boston Scientific, Bristol-Myers Squibb,
Cordis Corporation, Eli Lilly, The Medicines Company, Medtronic, Pfizer, and
sanofi-aventis. Dr. Turco has served as an adviser and speaker for and received
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
ZES  zotarolimus-eluting
stent(s)research support from Medtronic, Boston Scientific, and Abbott Vascular. Dr. Gurbel
has received research grants from AstraZeneca, Novartis/Portola, Pozen, Medtronic, aafety and efficacy outcomes among patients enrolled in
he ENDEAVOR III trial, comparing ZES and SES patient
ohorts over the entire 5-year study period in addition to the
nterval from 9 months to latest follow-up.
ethods
Study overview. The ENDEAVOR III trial was a prospec-
tive, multicenter trial designed to enroll 436 patients with
symptomatic ischemic heart disease undergoing single-
vessel percutaneous coronary intervention of a target lesion
with diameter between 2.5 and 3.5 mm and lesion length
14 and 27 mm. The primary endpoint evaluated in this
study was in-segment late lumen loss assessed by quantita-
tive coronary angiography at 8 months. Further detail
regarding enrollment criteria and study methods has been
previously reported (3). Patients were blinded to treatment
ssignment and were randomized to ZES or SES in a 3:1
ashion. Following revascularization, patients were recom-
ended per protocol to receive indefinite aspirin therapy
nd a minimum of 3 months of thienopyridine treatment.
ngiographic follow-up at 8 months was indicated per
rotocol for all patients and performed in 371 patients
85.1%). The study protocol (with pre-specified follow-up
hrough 5 years) was approved by the institutional ethics
ommittees at each enrolling site, and consecutive, eligi-
le patients signed written informed consent before the
nterventional procedure.
Data management and study endpoints. Clinical events
were assessed annually through patient contact with source
document verification and independent adjudication. Clin-
ical and angiographic results were submitted to a central
data coordinating facility (Harvard Clinical Research Insti-
tute, Boston, Massachusetts). Coronary angiograms per-
formed at baseline and any time during follow-up were
reviewed by an independent core laboratory (Beth Israel
Deaconess Medical Center, Boston, Massachusetts).
The primary objective of this patient-level analysis was to
compare 5-year clinical outcomes between patients treated
with ZES and SES against the background result of statisti-
cally significant differences in angiographic measures at 8
months. Clinical safety and efficacy endpoints included:
major adverse cardiac events (MACE) (the composite of
all-cause death, MI, emergency coronary artery bypass
surgery, and clinically driven TLR) and the individual
nd sanofi-aventis; and he has received consulting fees from AstraZeneca, Portola,
ozen, sanofi-aventis, Bayer, Eli Lilly, Daiichi Sankyo, National Institutes of Health,
nd Schering-Plough/Merck. Dr. Fitzgerald has served as a consultant for Abbott,
oston Scientific, Cordis Corporation, EndoTex, St. Jude Medical, Biosensor, ev3,
edtronic Cardiovascular, GlaxoSmithKline, ATI, Volcano Corporation, No-
adaq, AorTx, CardioMind, Cytograft Tissue Engineering, FlowCardia, Cardio
ptics, Optics, CardioMind, RTI Medical, SurModics, Hospira, and CatherosMed.
r. Leon has served as a consultant to Abbott Vascular, Boston Scientific, Cordis
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545components of the composite endpoint; stent thrombosis
(per Academic Research Consortium definition criteria (11)
and reported as early: 30 days, late: 31 days to 1 year, very
late: 1 year); clinically driven target vessel revasculariza-
tion; and target vessel failure (cardiac death, MI, and
clinically driven target vessel revascularization). Clinically
driven repeat revascularization was defined as revasculariza-
tion in the target vessel associated with a positive functional
ischemia study or ischemic symptoms and an angiographic
minimal lumen diameter stenosis 50% by quantitative
coronary angiography or as revascularization of a target
vessel with diameter stenosis70% by quantitative coronary
angiography without either ischemic symptoms or positive
functional study.
Statistical methods. All primary analyses were performed
according to the intention-to-treat principle. Categorical
variables were compared using Fisher exact test, and con-
tinuous variables were compared using a nonparametric test
(Wilcoxon score). As an exploratory evaluation of late-term
events beyond the initial study period, event rates were
compared between 9 months and 5 years. To maintain
Table 1. Selected Patient Clinical, Angiographic, and
ZE
Clinical characteristics
Age, yrs 61.4
Male 6
Diabetes mellitus 2
Hypertension 7
History of smoking 6
Hyperlipidemia 8
Prior myocardial infarction 1
Angina class III/IV 5
Prior percutaneous revascularization 2
Prior coronary bypass surgery
Angiographic and procedural characteristics
Target vessel
Left anterior descending artery 4
Left circumﬂex artery 2
Right coronary artery 3
Type B2/C lesions 6
Reference vessel diameter, mm 2.7
Lesion length, mm 14.9
Number of stents 1.1
Stent length, mm 22.3
Stent diameter, mm 3.0
Number of diseased vessels
1 6
2 2
3
Left ventricular ejection fraction 55
Values are mean SD (n) or % (n/N). Angina severity classified accord
SES sirolimus-eluting stent (s); ZES zotarolimus-eluting stent(s)balanced patient characteristics by randomization, patientswith events before 9 months were not excluded. The
Kaplan-Meier method was used to calculate the time to
clinical endpoints, and the log-rank test was used to
compare between-group differences. All statistical calcula-
tions were programmed using SAS (version 9.0 or above,
SAS Institute, Cary, North Carolina).
Results
Patient characteristics. The demographics of the study pop-
ulation and lesion characteristics are detailed in Table 1. No
significant differences were observed between treatment
cohorts other than a lower prevalence of men assigned to
treatment with ZES (65.3% vs. 81.4%, p  0.001). Among
the 436 patients treated, overall clinical characteristics
included: age: 61.5  10.8 years; diabetes: 29.4%; angina
class III/IV: 58.4%; and multivessel disease: 38.8%. The
average lesion length was 14.96  6.49 mm, and the mean
reference vessel diameter was 2.76  0.46 mm.
Dual antiplatelet therapy (aspirin and thienopyridine) ad-
edural Characteristics
323) SES (n  113) p Value
.58 (323) 61.73 11.59 (113) 0.80
1/323) 81.4 (92/113) 0.001
/323) 28.3 (32/113) 0.81
7/321) 74.3 (84/113) 0.54
2/319) 75.2 (85/113) 0.10
8/321) 86.7 (98/113) 0.46
/321) 20.7 (23/111) 0.89
6/263) 55.9 (52/93) 0.62
/323) 16.8 (19/113) 0.23
/323) 8.0 (9/113) 0.35
0.53
3/323) 39.8 (45/113)
/323) 28.3 (32/113)
5/323) 31.9 (36/113)
7/323) 56.6 (64/113) 0.05
6 (323) 2.79 0.46 (113) 0.49
0 (322) 14.95 7.28 (112) 0.96
0 (323) 1.19 0.45 (113) 0.28
8 (323) 23.02 7.69 (112) 0.33
8 (317) 3.12 0.35 (111) 0.21
0.40
1/323) 58.4 (66/113)
/323) 30.1 (34/113)
/323) 11.5 (13/113)
(307) 56.3 9.3 (110) 0.54
anadian Cardiovascular Society classification.Proc
S (n 
2 10
5.3 (21
9.7 (96
0.7 (22
6.5 (21
3.5 (26
9.9 (64
9.3 (15
2.6 (73
5.3 (17
1.2 (13
3.2 (75
5.6 (11
7.2 (21
5 0.4
6 6.2
4 0.4
1 6.1
7 0.3
2.2 (20
9.1 (94
8.7 (28
.7 9.1
ing to Cherence at 1 year was 17.5% and 16.5% (p  0.88) for ZES
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546Figure 1. 5-Year Cumulative Incidence of MACE, Cardiac Death/MI, and Clinically Driven TLR
Five-year cumulative incidence of major adverse cardiac event(s) (MACE) (A); cardiac death (CD)/myocardial infarction (MI) (B); and clinically driven target lesion
revascularization (TLR) (C) are shown. Cumulative event curves, produced by Kaplan-Meier methods, compare zotarolimus-eluting stents (ZES) to sirolimus-eluting
stent (SES) through 5-year follow-up. The p values at 270 and 1,800 days are log ranked.
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547and SES groups, respectively, and 7.0% and 6.4% (p  1.00)
t 5 years.
Overall 5-year and interval clinical outcomes. Through 5
ears, ascertainment of clinical events was complete for
5.0% (307 of 323) of ZES patients and 95.6% (108 of 113)
f SES patients. Compared with the SES group, events
ncluding all-cause mortality (5.2% vs. 13.0%, p  0.02),
I (1.0% vs. 4.6%, p 0.03), and the composite event rates
of cardiac death/MI (1.3% vs. 6.5%, p 0.009) and MACE
(14.0% vs. 22.2%, p  0.05) were significantly less common
among patients treated with ZES (Fig. 1, Table 2). Rates of
target lesion (8.1% ZES vs. 6.5% SES, p  0.68) (Fig. 1)
nd target vessel revascularization were similar between
reatment groups. Definite or probable stent thrombosis was
nfrequent and similar in both groups (0.7% ZES vs. 0.9%
ES, p  1.0).
At 9 months, the MACE rate was similar between
reatment arms, but after 9 months, MACE was signifi-
antly more frequent in the SES arm than in the ZES arm
16.7% vs. 7.8%, p  0.015). This was principally driven by
igher rates of all-cause death (4.6% vs. 13.0%, p  0.006)
nd cardiac death (0.3% vs. 2.8%, p  0.056) in the SES
ohort (Fig. 1, Table 3).
iscussion
In the ENDEAVOR III trial, although higher angio-
graphic restenosis was observed in ZES in the primary
results reported for the 9-month follow-up, cumulative
outcomes through 5 years demonstrated that the composite
endpoint of MACE and the important components of
death, as well as cardiac death and MI, favored treatment
with ZES compared with SES. After 9 months, composite
events were more common in the SES cohort and were
Table 2. 5-Year Clinical Outcomes in the ENDEAVOR III Trial
ZES
(n  307)
SES
(n  108) p Value
Death 5.2 (16) 13.0 (14) 0.02
Cardiac death 0.3 (1) 2.8 (3) 0.06
Myocardial infarction 1.0 (3) 4.6 (5) 0.03
Q-wave 0.3 (1) 0.9 (1) 0.45
Non–Q-wave 0.7 (2) 3.7 (4) 0.04
Cardiac death/myocardial infarction 1.3 (4) 6.5 (7) 0.009
Deﬁnite/probable stent thrombosis 0.7 (2) 0.9 (1) 1.00
0–360 days 0.3 (1) 0 (0) 1.00
361–1,800 days 0.3 (1) 0.9 (1) 0.45
Target lesion revascularization 8.1 (25) 6.5 (7) 0.68
Target vessel revascularization 16.9 (52) 13.0 (14) 0.36
Major adverse cardiac events 14.0 (43) 22.2 (24) 0.05
Target vessel failure 17.9 (55) 18.5 (20) 0.89
Values are % (n).
Abbreviations as in Table 1.principally driven by mortality (all-cause and cardiovascu- olar). Conversely, despite early differences in angiographic
outcome, rates of clinical restenosis beyond the period of
protocol-specified angiographic follow-up remain stable
with ZES compared with SES, resulting in similar late-
term efficacy as measured by the need for repeat procedures.
Considering the clinical need for DES to effectively
inhibit restenosis more than bare-metal stents, yet exhibit a
similar safety profile, an opportunity exists to develop newer
generation DES that may enhance biocompatibility, pro-
mote vessel healing and vasomotor function following PCI,
and permit a clinical safety profile similar to bare-metal
stents. Compared with alternative DES, the Endeavor ZES
consists of a thin-strut cobalt alloy platform and phospho-
rylcholine polymer that enable more rapid and complete
endothelial coverage and recovery of vasomotor reactivity
(12–16). Unlike most DES, however, the more rapid
elution kinetics of zotarolimus (95% within 14 days of
mplantation [3]) also permit greater angiographic late
umen loss compared with other DES yet less than conven-
ional bare-metal stents (3,17,18).
Whereas DES polymers have been implicated in delayed
ealing and late safety events, only recently has late efficacy
een evaluated. Among SES-treated patients undergoing
-year angiographic follow-up in the SIRTAX LATE
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization-Late) trial
19), for example, in-stent late lumen loss increased approx-
mately 2-fold compared with 8-month angiographic results
0.12  36 mm vs. 0.25  49 mm, p  0.001) that
paralleled similar increases in TLR. In the ISAR TEST-2
(Intracoronary Stenting and Angiographic Results–Test
Efficacy of 3 Limus-Eluting Stents) trial that included serial
angiographic follow-up (20), angiographic restenosis at 1
year and TLR were highest with ZES. However, accrual of
binary angiographic restenosis between 1 and 2 years was
more common for SES compared with ZES or a polymer-
free DES, corresponding to higher incident TLR between 1
and 2 years for SES versus comparator groups (1-2 Years:
SES: 3.5%, ZES: 0.7%, polymer-free DES: 0.9%). Progres-
sion of angiographic late loss has been similarly observed
with both paclitaxel- and everolimus-eluting stents (19,22).
In the present study, despite an 8-month angiographic
late loss nearly 3 higher than with SES (0.36  0.46 mm
vs. 0.13  0.33 mm, p  0.001), there was instead less
progression of clinical restenosis observed in the ZES
cohort beyond the initial 9 months, demonstrating a stable
and low rate of late TLR that is consistent among ZES
trials through the most recent follow-up (Table 4). Simi-
larly, results for SES in this analysis are in accord with
longitudinal data for SES represented in the SIRTAX
LATE (19) and SIRIUS (Sirolimus-Eluting Stent in Cor-
nary Lesions) (23) trials, demonstrating that progression of
LR beyond the first year accounts for approximately
ne-half of total TLR. In comparison, more than 80% of
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548total TLR for ZES in the ENDEAVOR III trial was
observed within 1 year of index revascularization. This
finding is consistent with the pooled analysis of 2,132
ZES-treated patients (42% angiographic follow-up) in
which a nearly identical proportion of overall TLR through
latest duration of follow-up occurs within the first year (21)
(Table 4).
Safety- and efficacy-related outcomes in the present study
for ZES parallel more recent comparative trial results with
other DES. Through 3-year follow-up in the ENDEAVOR
IV trial comparing ZES and paclitaxel-eluting stents (PES), a
significant difference in cardiac death and MI emerged favor-
ing treatment with ZES (7). In both the ENDEAVOR III
and ENDEAVOR IV trials, differences in MI emerged early,
possibly in part due to side branch closure related to stent
design (24). Also similar to the ENDEAVOR III trial, despite
igher angiographic restenosis and late lumen loss compared
ith PES, overall TLR did not statistically vary, and differ-
nces in TLR between 1 and 3 years were less disparate for
ES versus PES (4.5% ZES vs. 3.3% PES at 1 year; 6.5%
ES vs. 6.0% PES at 3 years, p  NS for all comparisons).
Table 3. Clinical Outcomes From 9 Months to 5 Years for
ZES and SES in the ENDEAVOR III Trial
ZES
(n  307)
SES
(n  108) p Value
Death 4.6 (14) 13.0 (14) 0.006
Cardiac death 0.3 (1) 2.8 (3) 0.06
Myocardial infarction 0.3 (1) 0.9 (1) 0.45
Q-wave 0.3 (1) 0.9 (1) 0.45
Non–Q-wave 0 (0) 0 (0) —
Cardiac death/myocardial infarction 0.7 (1) 3.7 (4) 0.04
Target lesion revascularization 2.9 (9) 3.7 (4) 0.75
Target vessel revascularization 7.5 (23) 7.4 (8) 1.00
Target vessel failure 8.1 (25) 10.2 (11) 0.55
ARC deﬁnite/probable ST 0.7 (2) 0.9 (1) 1.00
ARC ST all 1.0 (3) 3.7 (4) 0.08
MACE 7.8 (24) 16.7(18) 0.02
Values are % (n).
ARC  Academic Research Consortium; MACE  major adverse cardiac event(s); ST  stent
thrombosis; other abbreviations as in Tables 1 and 2.
Table 4. In-Stent Late Lumen Loss and Interval TLR Rates for DES in ENDE
Stent/Trial (Ref. #) N
In-Stent Lat
at 8 Month
Cypher SES/ENDEAVOR III (3) 113 0.15 0.34
Taxus PES/ENDEAVOR IV (17) 775 0.42 0.50
Endeavor ZES/ENDEAVOR II (18) 598 0.62 0.46
Endeavor ZES/ENDEAVOR III (3) 323 0.62 0.49
Endeavor ZES/ENDEAVOR IV (17) 773 0.67 0.49
Endeavor ZES/pooled ENDEAVOR program (21) 2,132 0.62 0.49
Values are mean SD (n) or % (n/N).DES drug-eluting stent(s); PES paclitaxel-eluting stent(s); TLR target lesions revascularization; othAltogether, these results support the effectiveness of ZES
ver long-term follow-up and are particularly suggestive of
heir relative effectiveness compared with alternative DES,
articularly beyond the period of angiographic surveillance.
onsidering the influence of angiographic surveillance on
ssessment of clinical restenosis (25,26), examination of
vents following the initial 9 months are insightful as they
re more likely related to clinical presentation than to
cheduled angiography. In this regard, several potential
easons exist why intermediate-term angiographic late lu-
en loss may not correlate with late efficacy. Although late
oss may be closely associated with TLR when measured
ver a similar time interval, early angiographic measures
ay be less predictive of late-term efficacy, particularly if
rogression of neointimal hyperplasia occurs. Moreover, a
linical threshold may exist for angiographic measures below
hich the risk of repeat revascularization is similar for DES,
nless driven by angiographic surveillance (25,26). As an
xample, in the ENDEAVOR III trial, qualifying angio-
raphic binary restenosis (i.e., 50% stenosis) was signifi-
antly more common with ZES, yet a similar proportion of
atients were identified with an in-segment percent diam-
ter stenosis of 70% or greater (26.5% ZES vs. 25.0% SES,
 1.00).
In addition, over 5 years of follow-up, differences in
mortality and MI developed favoring ZES compared with
SES aside from no difference in late efficacy. Nonetheless,
despite consistency of ZES outcomes in larger trials, the
sample size estimate for the ENDEAVOR III trial was
intended to evaluate a primary angiographic endpoint, and
the overall low event rates described for both groups limit
the statistical power for comparison of clinical events.
Therefore, these results should be considered hypothesis-
generating rather than definitive. Despite significantly lower
MI than in the SES cohort, it is uncertain how treatment
with ZES is associated with lower mortality; although a
trend toward lower cardiovascular-related mortality was
observed in the ZES cohort, differences in survival were
principally related to noncardiac causes.
In addition, these findings were observed among patients
undergoing elective percutaneous revascularization with rel-
Clinical Trials
TLR at 1 Year
TLR,
Latest Follow-Up
TLR, 1 Year to
Latest Follow-Up
3.6 (4/112) 6.5 (7/108) at 5 yrs 2.8 (3/108)
3.3 (25/757) 6.0 (44/734) at 3 yrs 2.6 (19/734)
5.9 (35/590) 7.5 (43/577) at 5 yrs 1.4 (8/577)
6.5 (21/321) 8.1 (25/307) at 5 yrs 1.3 (4/307)
4.5 (34/756) 6.5 (48/734) at 3 yrs 1.9 (14/734)
5.4 (113/2,102) 6.7 (139/2,063) at 3 yrs 1.3 (26/2,063)AVOR
e Loss
s (n)
(94)
(135)
(264)
(277)
(142)
(898)er abbreviations as in Tables 1 and 2.
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549atively simple to moderate lesion complexity, and thus the
results cannot be extended to high clinical risk and
complex lesion patient populations. In broader patient
populations as studied in the SORT OUT III (Compar-
ison of Zotarolimus-Eluting Stents and Sirolimus-Eluting
Stents in Patients With Coronary Artery Disease) trial
(n  2,332) (10), for example, significant differences in
all-cause mortality, TLR, and MI instead favored treatment
with SES at 18-months follow-up. Although that study was
also underpowered for differences in individual endpoints,
the absolute differences observed at 18 months were smaller
in magnitude compared with those observed in the present
study at 5 years (e.g., SORT OUT III vs. present study: MI:
1% vs. 2%, p  0.03; death: 3% vs. 4%, p  0.04). In
another inclusive randomized trial comparing ZES, PES,
and SES, 12-month MACE outcomes did not differ sig-
nificantly between SES and ZES groups (27). Although
significantly lower MACE with ZES compared with PES
in that study is generally consistent with the lower incidence
of target vessel failure observed in the 3-year follow-up of
the ENDEAVOR IV trial (7), the absence of differences
in MACE between ZES and SES represented numeri-
cally (but nonsignificantly) lower death or MI with ZES
and significantly lower TLR with SES. Most important,
emergence of differences in safety endpoints or differen-
tial trends in repeat revascularization were more com-
monly identified in the ENDEAVOR trials over a much
later term than were reported in the SORT OUT and
ZEST (Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent With Sirolimus-Eluting and
Paclitaxel-Eluting Stent for Coronary Lesions) trials
(27). Aside from quite dissimilar timing of event reporting and
incomparable study populations, further differences in trial
methods and endpoint ascertainment (e.g., absence of in-
hospital MI reporting, angiographic surveillance, or direct
patient contact in follow-up in SORT OUT III) preclude
more direct comparison of results between these trials.
Conclusions
Despite significantly higher 8-month angiographic late
lumen loss, rates of clinical restenosis during later follow-up
remain stable with ZES compared with SES, resulting in
relatively small (1.5% absolute) overall differences in clinical
restenosis rates at 5 years. These findings are consistent with
additional recent studies identifying differential temporal
progression of angiographic measures and clinical events
among DES, and challenge earlier models relating early
angiographic measures to longer-term requirement for re-
peat procedures. Furthermore, restenosis risk was dissociated
from clinical endpoints of death and MI that favored treatment
with ZES, contesting the notion that less favorable early
angiographic surrogates of efficacy accurately predict important
clinical events.Reprint requests and correspondence: Dr. David E. Kandzari,
Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta,
Georgia 30309. E-mail: david.kandzari@piedmont.org.
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